ATEZOLIZUMAB
atezolizumab 1.875 g/15 mL injection, 15 mL vial
ATEZOLIZUMAB (14268Y)
14268Y
Manner of administration:Injection
Restriction 10216
Indication: Stage IV (metastatic) non-small cell lung cancer (NSCLC)
Treatment phase: Continuing first-line treatment of metastatic disease - 3 weekly treatment regimen
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 1 | # of repeats: 7 | DPMQ: $6,747.37 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Tecentriq SC | |||||